Ipilimumab: Bristol-Myers, Medarex cancer drug delayed
Ipilimumab, the fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), is in clinical trials for the treatment of advanced melanoma, but Reuters is reporting:
Bristol-Myers Squibb Co and Medarex Inc said Friday they will delay seeking approval of their experimental treatment for advanced melanoma after U.S. health regulators requested additional data on the biotechnology drug.
Because of this, an approval application will not be submitted this year.
Comments